You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOndansetron
Accession NumberDB00904  (APRD00481)
TypeSmall Molecule
GroupsApproved
DescriptionA competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]
Structure
Thumb
Synonyms
Zofran odt
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Ondansetrontablet4 mgoralActavis Pharma Company2009-06-29Not applicableCanada
Act Ondansetrontablet8 mgoralActavis Pharma Company2009-06-29Not applicableCanada
Ag-ondansetrontablet4 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-ondansetrontablet8 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ava-ondansetrontablet8 mgoralAvanstra Inc2011-08-18Not applicableCanada
Bio-ondansetrontablet4 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-ondansetrontablet8 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-ondansetrontablet8 mgoralDominion Pharmacal2008-04-17Not applicableCanada
Dom-ondansetrontablet4 mgoralDominion Pharmacal2008-04-17Not applicableCanada
Ipg-ondansetrontablet4 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-ondansetrontablet8 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-ondansetrontablet8 mgoralJamp Pharma Corporation2008-09-26Not applicableCanada
Jamp-ondansetronsolution2 mgintravenousJamp Pharma Corporation2014-03-14Not applicableCanada
Jamp-ondansetronsolution2 mgintravenousJamp Pharma Corporation2014-03-14Not applicableCanada
Jamp-ondansetrontablet4 mgoralJamp Pharma Corporation2008-09-26Not applicableCanada
Mar-ondansetrontablet8 mgoralMarcan Pharmaceuticals Inc2012-12-21Not applicableCanada
Mar-ondansetrontablet4 mgoralMarcan Pharmaceuticals Inc2012-12-21Not applicableCanada
Mint-ondansetrontablet4 mgoralMint Pharmaceuticals Inc2008-04-23Not applicableCanada
Mint-ondansetrontablet8 mgoralMint Pharmaceuticals Inc2008-04-23Not applicableCanada
Mylan-ondansetrontablet4 mgoralMylan Pharmaceuticals Ulc2007-07-20Not applicableCanada
Mylan-ondansetrontablet8 mgoralMylan Pharmaceuticals Ulc2007-07-20Not applicableCanada
Mylan-ondansetron Injectionsolution2.00 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-ondansetron Injectionsolution2.00 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Nat-ondansetrontablet8 mgoralNatco Pharma (Canada) Inc2015-03-18Not applicableCanada
Nat-ondansetrontablet4 mgoralNatco Pharma (Canada) Inc2015-03-18Not applicableCanada
Nu-ondansetrontablet4 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-ondansetrontablet8 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-ondansetronsolution4 mgoralNu Pharm IncNot applicableNot applicableCanada
Ondansetrontablet8 mgoralMeliapharm Inc2011-04-082014-06-25Canada
Ondansetrontablet8 mgoralPro Doc Limitee2009-06-25Not applicableCanada
Ondansetronsolution4 mgoralAa Pharma Inc2008-03-04Not applicableCanada
Ondansetrontablet4 mgoralSanis Health Inc2014-03-18Not applicableCanada
Ondansetrontablet8 mgoralSanis Health Inc2014-03-18Not applicableCanada
Ondansetrontablet4 mgoralMeliapharm Inc2011-04-082014-06-25Canada
Ondansetron Hydrochloride Dihydrate Injectionsolution2 mgintravenousSandoz Canada Incorporated2012-06-28Not applicableCanada
Ondansetron Injectionsolution2 mgintravenousTeva Canada Limited2006-05-18Not applicableCanada
Ondansetron Injectionsolution2 mgintravenousTeva Canada Limited2006-05-18Not applicableCanada
Ondansetron Injection USPsolution2 mgintravenousAccord Healthcare IncNot applicableNot applicableCanada
Ondansetron Injection USPsolution2 mgintravenousAccord Healthcare IncNot applicableNot applicableCanada
Ondansetron Injection USP -(preservative Free)solution2 mgintravenousHospira Healthcare Corporation2006-06-21Not applicableCanada
Ondansetron Injection USP -(preservative Free)solution2 mgintravenousSandoz Canada Incorporated2006-04-19Not applicableCanada
Ondansetron Injection USP -(with Preservative)solution2 mgintravenousSandoz Canada Incorporated2006-04-19Not applicableCanada
Ondansetron Injection USP -(with Preservatives)solution2 mgintravenousHospira Healthcare Corporation2006-06-21Not applicableCanada
Ondansetron Injection, USPsolution2.00 mgintravenousAGILA SPECIALTIES PRIVATE LIMITED2009-08-202012-07-05Canada
Ondansetron Injection, USPsolution2 mgintravenousMylan Pharmaceuticals Ulc2013-05-09Not applicableCanada
Ondansetron Injection, USPsolution2 mgintravenousMylan Pharmaceuticals Ulc2013-05-09Not applicableCanada
Ondansetron Injection, USPsolution2.00 mgintravenousAGILA SPECIALTIES PRIVATE LIMITED2008-03-262012-07-05Canada
Ondansetron Omega -(preservative Free - Single Dose Vials)liquid2 mgintravenousOmega Laboratories Ltd2006-05-02Not applicableCanada
Ondansetron Omega -(with Preservative - Multidose Vial)liquid2 mgintravenousOmega Laboratories Ltd2006-05-11Not applicableCanada
Ondansetron-odantablet4 mgoralOdan Laboratories Ltd2008-05-092015-12-21Canada
Ondansetron-odantablet8 mgoralOdan Laboratories Ltd2008-05-092015-12-21Canada
Ondissolve Odffilm, soluble8 mgoralTakeda Canada Inc2013-02-08Not applicableCanada
Ondissolve Odffilm, soluble4 mgoralTakeda Canada Inc2013-02-08Not applicableCanada
PHL-ondansetrontablet4 mgoralPharmel Inc2006-07-21Not applicableCanada
PHL-ondansetrontablet8 mgoralPharmel Inc2006-07-21Not applicableCanada
PMS-ondansetrontablet4 mgoralPharmascience Inc2006-04-19Not applicableCanada
PMS-ondansetrontablet8 mgoralPharmascience Inc2006-04-19Not applicableCanada
Priva-ondansetrontablet4 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-ondansetrontablet8 mgoralPharmapar IncNot applicableNot applicableCanada
Ran-ondansetrontablet8 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-09-12Not applicableCanada
Ran-ondansetrontablet4 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-09-12Not applicableCanada
Ratio-ondansetrontablet4 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-04-192015-10-26Canada
Ratio-ondansetrontablet8 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-04-192015-10-26Canada
Riva-ondansetrontablet4 mgoralLaboratoire Riva Inc2011-10-182015-07-22Canada
Riva-ondansetrontablet8 mgoralLaboratoire Riva Inc2011-10-182015-07-22Canada
Sandoz Ondansetrontablet4 mgoralSandoz Canada Incorporated2006-04-19Not applicableCanada
Sandoz Ondansetrontablet8 mgoralSandoz Canada Incorporated2006-04-19Not applicableCanada
Sandoz Ondansetron ODTtablet (orally disintegrating)4 mgoralSandoz Canada Incorporated2015-11-23Not applicableCanada
Sandoz Ondansetron ODTtablet (orally disintegrating)8 mgoralSandoz Canada Incorporated2015-11-23Not applicableCanada
Septa-ondansetrontablet4 mgoralSepta Pharmaceuticals Inc2012-09-12Not applicableCanada
Septa-ondansetrontablet8 mgoralSepta Pharmaceuticals Inc2012-09-12Not applicableCanada
Teva-ondansetrontablet8 mgoralTeva Canada Limited2006-05-26Not applicableCanada
Teva-ondansetrontablet4 mgoralTeva Canada Limited2006-05-26Not applicableCanada
Van-ondansetrontablet4 mgoralVanc Pharmaceuticals Inc2016-04-18Not applicableCanada
Van-ondansetrontablet8 mgoralVanc Pharmaceuticals Inc2016-04-18Not applicableCanada
Zofrantablet, orally disintegrating4 mg/1oralCardinal Health1999-01-27Not applicableUs
Zofraninjection2 mg/mLintramuscular; intravenousGlaxo Smith Kline Llc1991-02-04Not applicableUs
Zofransolution2 mgintravenousNovartis Pharmaceuticals Canada Inc1999-08-01Not applicableCanada
Zofrantablet, film coated4 mg/1oralGlaxo Smith Kline Llc1993-02-11Not applicableUs
Zofransolution4 mgoralNovartis Pharmaceuticals Canada Inc1996-11-13Not applicableCanada
Zofrantablet, film coated8 mg/1oralGlaxo Smith Kline Llc1993-02-11Not applicableUs
Zofrantablet4 mgoralNovartis Pharmaceuticals Canada Inc1998-03-30Not applicableCanada
Zofrantablet, orally disintegrating8 mg/1oralREMEDYREPACK INC.2011-12-19Not applicableUs
Zofransolution4 mg/5mLoralGlaxo Smith Kline Llc1997-02-05Not applicableUs
Zofrantablet8 mgoralNovartis Pharmaceuticals Canada Inc1997-04-14Not applicableCanada
Zofran Inj 2mg/mlliquid2 mgintravenousGlaxo Canada Inc1991-12-311999-08-12Canada
Zofran ODTtablet (orally disintegrating)8 mgoralNovartis Pharmaceuticals Canada Inc1999-03-31Not applicableCanada
Zofran ODTtablet, orally disintegrating4 mg/1oralGlaxo Smith Kline Llc1999-03-01Not applicableUs
Zofran ODTtablet, orally disintegrating8 mg/1oralGlaxo Smith Kline Llc1999-03-01Not applicableUs
Zofran ODTtablet (orally disintegrating)4 mgoralNovartis Pharmaceuticals Canada Inc1999-03-31Not applicableCanada
Zofran Tab 4mgtablet4 mgoralGlaxo Canada Inc1991-12-311998-07-30Canada
Zofran Tab 8mgtablet8 mgoralGlaxo Canada Inc1991-12-311998-07-30Canada
Zuplenzfilm, soluble8 mg/1oralPraelia Pharmaceuticals Inc2010-07-052015-11-30Us
Zuplenzfilm, soluble4 mg/1oralGalena Biopharma, Inc.2014-10-08Not applicableUs
Zuplenzfilm, soluble8 mg/1oralGalena Biopharma, Inc.2014-10-08Not applicableUs
Zuplenzfilm, soluble4 mg/1oralPraelia Pharmaceuticals Inc2010-07-052015-11-30Us
Zym-ondansetrontablet4 mgoralZymcan Pharmaceuticals Inc2010-04-162014-06-16Canada
Zym-ondansetrontablet8 mgoralZymcan Pharmaceuticals Inc2010-04-162014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ondansetrontablet4 mgoralApotex Inc2006-11-16Not applicableCanada
Apo-ondansetrontablet8 mgoralApotex Inc2006-11-16Not applicableCanada
Ondansetrontablet, film coated4 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Ondansetrontablet24 mg/1oralWest ward Pharmaceutical Corp2008-01-01Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralRebel Distributors Corp.2007-08-13Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralRebel Distributors Corp2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralAidarex Pharmaceuticals LLC2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralCardinal Health2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralCitron Pharma LLC2010-04-12Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralRnabaxy Pharmaceuticals Inc.2012-01-10Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousThe Medicines Company2009-11-18Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralBlue Point Laboratories2014-03-13Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPreferred Pharmaceuticals Inc.2015-10-16Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not applicableUs
Ondansetrontablet, film coated4 mg/1oralProficient Rx LP2007-06-25Not applicableUs
Ondansetronsolution4 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2007-11-30Not applicableUs
Ondansetrontablet4 mg/1oralMajor Pharmaceuticals2008-01-01Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousHeritage Pharmaceuticals2015-11-09Not applicableUs
Ondansetrontablet, film coated4 mg/1oralCardinal Health2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-13Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2012-12-21Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralProficient Rx LP2007-08-31Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralMylan Pharmaceuticals Inc.2012-09-10Not applicableUs
Ondansetrontablet, film coated4 mg/1oralClinical Solutions Wholesale2007-06-25Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousSun Pharmaceutical Industries Limited2006-12-26Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2009-11-18Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPreferred Pharmaceuticals, Inc.2013-08-27Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2007-01-19Not applicableUs
Ondansetrontablet, film coated8 mg/1oralSandoz Inc2007-06-25Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-10-142016-04-05Us
Ondansetrontablet, orally disintegrating4 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-10Not applicableUs
Ondansetrontablet, film coated4 mg/1oralCardinal Health2012-12-05Not applicableUs
Ondansetrontablet, film coated8 mg/1oralMylan Institutional Inc.2007-07-09Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not applicableUs
Ondansetrontablet, film coated8 mg/1oralActavis Inc.2007-07-27Not applicableUs
Ondansetrontablet, film coated8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralProficient Rx LP2007-08-13Not applicableUs
Ondansetrontablet, film coated24 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-06-25Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-192015-12-29Us
Ondansetrontablet, orally disintegrating4 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralStat Rx USA2009-10-27Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-08-30Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2006-11-22Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralREMEDYREPACK INC.2013-06-10Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralRebel Distributors Corp2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralAidarex Pharmaceuticals LLC2007-06-27Not applicableUs
Ondansetrontablet, film coated4 mg/1oralCardinal Health2007-07-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralCitron Pharma LLC2010-04-12Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralRnabaxy Pharmaceuticals Inc.2012-01-10Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousThe Medicines Company2009-11-18Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralBlue Point Laboratories2014-03-13Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPreferred Pharmaceuticals, Inc.2015-03-31Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralDispensing Solutions, Inc.2007-06-27Not applicableUs
Ondansetrontablet, film coated8 mg/1oralLife Line Home Care Services, Inc.2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralMylan Pharmaceuticals Inc.2012-09-10Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralREMEDYREPACK INC.2016-02-02Not applicableUs
Ondansetronsolution4 mg/5mLoralSilarx Pharmaceuticals, Inc2011-01-27Not applicableUs
Ondansetrontablet8 mg/1oralMajor Pharmaceuticals2008-01-01Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-08-31Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousHeritage Pharmaceuticals2012-06-15Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2010-11-19Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralMedsource Pharmaceuticals2010-04-12Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralREMEDYREPACK INC.2014-11-13Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralProficient Rx LP2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralbryant ranch prepack2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralCardinal Health2007-08-31Not applicableUs
Ondansetrontablet, film coated8 mg/1oralClinical Solutions Wholesale2007-06-25Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousSun Pharmaceutical Industries Limited2006-12-26Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2009-11-18Not applicableUs
Ondansetronsolution4 mg/5mLoralAurobindo Pharma Limited2007-11-28Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPreferred Pharmaceuticals, Inc.2013-07-24Not applicableUs
Ondansetronsolution4 mg/5mLoralAtlantic Biologicals Corps2010-12-17Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousSandoz Inc2007-06-27Not applicableUs
Ondansetroninjection, solution2 mg/mLintravenousREMEDYREPACK INC.2014-01-092016-04-05Us
Ondansetrontablet4 mg/1oralWest ward Pharmaceutical Corp2008-01-01Not applicableUs
Ondansetronsolution4 mg/5mLoralNorth Star Rx Llc2007-11-28Not applicableUs
Ondansetrontablet, film coated4 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ondansetrontablet, film coated8 mg/1oralProficient Rx LP2007-06-25Not applicableUs
Ondansetrontablet, film coated4 mg/1oralAscend Laboratories, LLC2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-06-27Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-192015-12-29Us
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPhysicians Total Care, Inc.2008-05-08Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousGland Pharma Limited2009-09-25Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2006-11-22Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralDispensing Solutions, Inc.2007-06-27Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp2006-12-26Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralRebel Distributors Corp2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralRx Change Co.2014-11-26Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralCardinal Health2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralUnit Dose Services2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralClinical Solutions Wholesale2007-08-02Not applicableUs
Ondansetrontablet, film coated4 mg/1oralRanbaxy Pharmaceuticals Inc.2007-06-25Not applicableUs
Ondansetrontablet, film coated4 mg/1oralbryant ranch prepack2007-06-25Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousQilu Pharmaceutical Co., Ltd.2014-09-08Not applicableUs
Ondansetrontablet, film coated4 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-06-25Not applicableUs
Ondansetroninjection, solution4 mg/2mLintramuscular; intravenousBD Rx Inc.2013-08-23Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2006-12-26Not applicableUs
Ondansetrontablet, film coated4 mg/1oralDIRECT RX2016-03-23Not applicableUs
Ondansetrontablet, film coated4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-07-27Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousHeritage Pharmaceuticals2015-11-09Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2010-11-19Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralMedsource Pharmaceuticals2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralREMEDYREPACK INC.2015-02-26Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralProficient Rx LP2007-06-27Not applicableUs
Ondansetrontablet, film coated4 mg/1oralMylan Pharmaceuticals Inc.2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPd Rx Pharmaceuticals, Inc.2007-06-27Not applicableUs
Ondansetrontablet, film coated8 mg/1oralCardinal Health2012-12-05Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralClinical Solutions Wholesale2007-08-31Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralSun Pharmaceutical Industries Limited2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralAurobindo Pharma Limited2010-04-12Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-27Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralSandoz Inc2007-08-31Not applicableUs
Ondansetroninjection, solution2 mg/mLintravenousREMEDYREPACK INC.2014-02-13Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-21Not applicableUs
Ondansetroninjection2 mg/mLintravenousPhysicians Total Care, Inc.2008-05-08Not applicableUs
Ondansetrontablet8 mg/1oralWest ward Pharmaceutical Corp2008-01-01Not applicableUs
Ondansetronsolution4 mg/5mLoralAtlantic Biologicals Corps2010-12-17Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralRebel Distributors Corp2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralCardinal Health2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralProficient Rx LP2010-04-12Not applicableUs
Ondansetronsolution4 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2010-12-17Not applicableUs
Ondansetrontablet, film coated8 mg/1oralAscend Laboratories, LLC2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-06-27Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPreferred Pharmaceuticals, Inc2012-02-142015-12-29Us
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not applicableUs
Ondansetrontablet, film coated8 mg/1oralRanbaxy Pharmaceuticals Inc.2007-06-25Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousGland Pharma Limited2012-06-15Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralProficient Rx LP2007-08-02Not applicableUs
Ondansetrontablet, film coated4 mg/1oralSandoz Inc2007-06-25Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp2006-12-26Not applicableUs
Ondansetrontablet, film coated4 mg/1oralSTAT Rx USA LLC2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralRx Change Co.2014-12-02Not applicableUs
Ondansetrontablet, film coated4 mg/1oralMylan Institutional Inc.2007-07-09Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralClinical Solutions Wholesale2007-08-02Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2015-10-19Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralProficient Rx LP2010-04-12Not applicableUs
Ondansetrontablet, film coated4 mg/1oralbryant ranch prepack2007-06-25Not applicableUs
Ondansetrontablet, film coated8 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-06-25Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2006-12-26Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralPhysicians Total Care, Inc.2007-01-16Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2013-05-04Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralHHS/Program Support Center/Supply Service Center2011-07-26Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-08-30Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not applicableUs
Ondansetrontablet, film coated4 mg/1oralActavis Inc.2007-07-27Not applicableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-21Not applicableUs
Ondansetrontablet, film coated8 mg/1oralMylan Pharmaceuticals Inc.2007-06-25Not applicableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousHeritage Pharmaceuticals2012-06-15Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-31Not applicableUs
Ondansetrontablet, orally disintegrating4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-26Not applicableUs
Ondansetrontablet, film coated8 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-23Not applicableUs
Ondansetronsolution4 mg/5mLoralApotex Corp2008-03-13Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralSun Pharmaceutical Industries Limited2007-08-02Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralAurobindo Pharma Limited2010-04-12Not applicableUs
Ondansetrontablet, film coated8 mg/1oralProficient Rx LP2007-06-25Not applicableUs
Ondansetrontablet, orally disintegrating8 mg/1oralSandoz Inc2007-08-13Not applicableUs
Ondansetron HCltablet, coated4 mg/31oralNorthwind Pharmaceuticals2014-03-17Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralDispensing Solutions, Inc.2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralUnit Dose Services2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralH.J. Harkins Company, Inc.2007-06-25Not applicableUs
Ondansetron Hydrochloridesolution4 mg/5mLoralRoxane Laboratories, Inc2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralbryant ranch prepack2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralMed Vantx, Inc.2007-07-31Not applicableUs
Ondansetron Hydrochloridesolution4 mg/5mLoralCarilion Materials Management2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Ondansetron Hydrochloridetablet, film coated24 mg/1oralAurobindo Pharma Limited2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralDr.Reddy's Laboratories Limited2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet4 mg/1oralKAISER FOUNDATION HOSPITALS2011-09-12Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintravenousHeritage Pharmaceuticals Inc.2013-01-18Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintramuscular; intravenousWOCKHARDT USA LLC2006-12-27Not applicableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousMylan Institutional LLC2014-12-29Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintramuscular; intravenousLannett Company, Inc.2010-07-01Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralPhysicians Total Care, Inc.2007-07-30Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralTeva Pharmaceuticals USA Inc2007-07-03Not applicableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousClaris Lifesciences Inc.2013-03-13Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralDispensing Solutions, Inc.2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralRebel Distributors Corp2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet4 mg/1oralUnit Dose Services2007-01-06Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2011-03-28Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralDispensing Solutions, Inc.2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-03Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Ondansetron Hydrochloridetablet, film coated24 mg/1oralDr.Reddy's Laboratories Limited2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet8 mg/1oralKAISER FOUNDATION HOSPITALS2011-09-12Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintravenousHeritage Pharmaceuticals Inc.2014-02-24Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralAidarex Pharmaceuticals LLC2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralCardinal Health2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet4 mg/1oralREMEDYREPACK INC.2011-09-01Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralCitron Pharma LLC2007-07-31Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintramuscular; intravenousWOCKHARDT USA LLC2006-12-27Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-06-14Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralPreferred Pharmaceuticals, Inc.2012-06-12Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralProficient Rx LP2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralRebel Distributors Corp2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralSun Pharmaceutical Industries Limited2007-06-25Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralAurobindo Pharma Limited2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2011-03-28Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralPhysicians Total Care, Inc.2006-12-29Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralBlenheim Pharmacal, Inc.2013-12-17Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintramuscular; intravenousWockhardt Limited2006-12-27Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintravenousHeritage Pharmaceuticals Inc.2014-02-19Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-04-03Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralNorthwind Pharmaceuticals2014-12-30Not applicableUs
Ondansetron Hydrochloridetablet, orally disintegrating4 mg/1oralbryant ranch prepack2007-06-27Not applicableUs
Ondansetron Hydrochloridesolution4 mg/5mLoralPrecision Dose Inc.2010-05-112016-04-05Us
Ondansetron Hydrochloridesolution2 mg/mLintravenousREMEDYREPACK INC.2014-07-07Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralAidarex Pharmaceuticals LLC2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet8 mg/1oralREMEDYREPACK INC.2011-11-15Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralCitron Pharma LLC2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralDIRECT RX2014-01-01Not applicableUs
Ondansetron Hydrochloridetablet8 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralAurobindo Pharma Limited2007-07-31Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralPreferred Pharmaceuticals, Inc.2012-06-12Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintravenousREMEDYREPACK INC.2013-07-05Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralDr.Reddy's Laboratories Limited2006-12-26Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintravenousHeritage Pharmaceuticals Inc.2012-12-13Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet, film coated8 mg/1oralSun Pharmaceutical Industries Limited2007-06-25Not applicableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousMylan Institutional LLC2014-12-29Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralTeva Pharmaceuticals USA Inc2007-07-032015-12-29Us
Ondansetron Hydrochloridetablet, film coated24 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2011-03-28Not applicableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousClaris Lifesciences Inc.2013-03-13Not applicableUs
Ondansetron Hydrochlorideinjection2 mg/mLintramuscular; intravenousWockhardt Limited2006-12-27Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralREMEDYREPACK INC.2014-03-11Not applicableUs
Ondansetron Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not applicableUs
Ondansetron Hydrochloridetablet, film coated4 mg/1oralbryant ranch prepack2007-06-25Not applicableUs
Ondansetron Hydrochloridesolution4 mg/5mLoralPrecision Dose Inc.2015-02-27Not applicableUs
Ondansetron Hydrochloridetablet8 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Ondansetron Hydrochloride and Dextroseinjection, solution32 mg/50mLintravenousWest ward Pharmaceutical Corp2009-08-04Not applicableUs
Ondansetron Hydrochloride and Dextroseinjection, solution32 mg/50mLintravenousPfizer Labs, Division Of Pfizer Inc.2009-05-01Not applicableUs
Ondansetron Hydrochloride and Dextroseinjection, solution32 mg/50mLintravenousClaris Lifesciences, Inc2009-04-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ZophrenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ondansetron hydrochloride
ThumbNot applicableDBSALT001248
Ondansetron hydrochloride dihydrate
ThumbNot applicableDBSALT000921
Categories
UNII4AF302ESOS
CAS number99614-02-5
WeightAverage: 293.363
Monoisotopic: 293.152812245
Chemical FormulaC18H19N3O
InChI KeyInChIKey=FELGMEQIXOGIFQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
IUPAC Name
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
SMILES
CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents
Substituents
  • Carbazole
  • Indole
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzenoid
  • Substituted pyrrole
  • N-substituted imidazole
  • N-methylpyrrole
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrole
  • Imidazole
  • Azole
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
PharmacodynamicsOndansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
Mechanism of actionOndansetron is a selective serotonin 5-HT3 receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Related Articles
AbsorptionOndansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.
Volume of distributionNot Available
Protein binding70%-76% (Plasma protein binding)
Metabolism

Hepatic

Route of eliminationNot Available
Half life5.7 hours
Clearance
  • 0.38 L/h/kg [Normal Adult Volunteers (19-40 yrs)]
  • 0.32 L/h/kg [Normal Adult Volunteers (61-74 yrs)]
  • 0.26 L/h/kg [Normal Adult Volunteers (>=75 yrs)]
ToxicityLow blood pressure and fainting, sudden blindness, severe constipation
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7019
P-glycoprotein inhibitor IInhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.8807
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7456
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.647
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5954
Ames testNon AMES toxic0.5463
CarcinogenicityNon-carcinogens0.9676
BiodegradationNot ready biodegradable0.9884
Rat acute toxicity2.4555 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7054
hERG inhibition (predictor II)Inhibitor0.7926
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Par pharmaceutical
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Glenmark generics ltd
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Akorn strides llc
  • Apotex inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Emcure pharmaceuticals ltd
  • Gland pharma ltd
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Lannett holdings inc
  • Luitpold pharmaceuticals inc
  • Pharmaforce inc
  • Pliva hrvatska doo
  • Sandoz canada inc
  • Spectrum pharmaceuticals
  • Wockhardt ltd
  • Bedford laboratories
  • Claris lifesciences ltd
  • Teva parenteral medicines inc
  • Baxter healthcare corp
  • Apotex inc richmond hill
  • Taro pharmaceuticals ireland ltd
  • Roxane laboratories inc
  • Taro pharmaceutical industries ltd
  • Dr reddys laboratories ltd
  • Natco pharma ltd
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous2 mg/mL
Injection, solutionintramuscular; intravenous4 mg/2mL
Solutionoral4 mg
Tabletoral24 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Tablet, coatedoral4 mg/31
Injectionintravenous2 mg/mL
Injection, solutionintramuscular2 mg/mL
Injection, solutionintramuscular; intravenous2 mg/mL
Injection, solutionintravenous2 mg/mL
Solutionintramuscular; intravenous2 mg/mL
Solutionintravenous2 mg/mL
Solutionoral4 mg/5mL
Tablet, film coatedoral24 mg/1
Tablet, film coatedoral8 mg/1
Injection, solutionintravenous32 mg/50mL
Solutionintravenous2 mg
Solutionintravenous2.00 mg
Liquidintravenous2 mg
Film, solubleoral4 mg
Film, solubleoral8 mg
Tabletoral4 mg
Tabletoral8 mg
Tablet (orally disintegrating)oral4 mg
Tablet (orally disintegrating)oral8 mg
Tablet, film coatedoral4 mg/1
Tablet, orally disintegratingoral4 mg/1
Tablet, orally disintegratingoral8 mg/1
Film, solubleoral4 mg/1
Film, solubleoral8 mg/1
Prices
Unit descriptionCostUnit
Ondansetron 30 8 mg Dispersible Tablet Box1158.51USD box
Zofran ODT 30 4 mg Dispersible Tablet Box782.26USD box
Ondansetron 30 4 mg Dispersible Tablet Box695.53USD box
Ondansetron hcl powder177.0USD g
Ondansetron hcl 24 mg tablet105.5USD tablet
Zofran 8 mg tablet45.16USD tablet
Zofran odt 8 mg tablet41.76USD tablet
Ondansetron hcl 8 mg tablet40.75USD tablet
Ondansetron odt 8 mg tablet37.13USD tablet
Zofran 4 mg tablet27.11USD tablet
Ondansetron hcl 4 mg tablet25.07USD tablet
Zofran odt 4 mg tablet25.07USD tablet
Zofran 8 mg Tablet23.02USD tablet
Zofran Odt 8 mg Disintegrating Tablet22.49USD tablet
Ondansetron odt 4 mg tablet22.3USD tablet
Zofran 4 mg Tablet15.09USD tablet
Zofran Odt 4 mg Disintegrating Tablet14.74USD tablet
Zofran 2 mg/ml vial12.82USD ml
Zofran 4 mg/2 ml vial12.82USD ml
Apo-Ondansetron 8 mg Tablet12.06USD tablet
Co Ondansetron 8 mg Tablet12.06USD tablet
Jamp-Ondansetron 8 mg Tablet12.06USD tablet
Mint-Ondansetron 8 mg Tablet12.06USD tablet
Mylan-Ondansetron 8 mg Tablet12.06USD tablet
Novo-Ondansetron 8 mg Tablet12.06USD tablet
Ondansetron-Odan 8 mg Tablet12.06USD tablet
Phl-Ondansetron 8 mg Tablet12.06USD tablet
Pms-Ondansetron 8 mg Tablet12.06USD tablet
Ran-Ondansetron 8 mg Tablet12.06USD tablet
Ratio-Ondansetron 8 mg Tablet12.06USD tablet
Sandoz Ondansetron 8 mg Tablet12.06USD tablet
Zofran 2 mg/ml11.12USD ml
Apo-Ondansetron 4 mg Tablet7.9USD tablet
Co Ondansetron 4 mg Tablet7.9USD tablet
Jamp-Ondansetron 4 mg Tablet7.9USD tablet
Mint-Ondansetron 4 mg Tablet7.9USD tablet
Mylan-Ondansetron 4 mg Tablet7.9USD tablet
Novo-Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron-Odan 4 mg Tablet7.9USD tablet
Phl-Ondansetron 4 mg Tablet7.9USD tablet
Pms-Ondansetron 4 mg Tablet7.9USD tablet
Ran-Ondansetron 4 mg Tablet7.9USD tablet
Ratio-Ondansetron 4 mg Tablet7.9USD tablet
Sandoz Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron (Preserved) 2 mg/ml6.23USD ml
Ondansetron (Unpreserved) 2 mg/ml6.23USD ml
Ondansetron (With Preservative) 2 mg/ml6.23USD ml
Ondansetron Omega (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron Omega (With Preservative) 2 mg/ml6.23USD ml
Ondansetron hcl 4 mg/2 ml vial3.13USD ml
Zofran 0.8 mg/ml Solution2.3USD ml
Apo-Ondansetron 0.8 mg/ml Solution1.53USD ml
Ondansetron 32 mg/50 ml bag0.86USD ml
Ondansetron hcl 32 mg/50 ml bg0.42USD ml
Ondansetron 40 mg/20 ml vial0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2205600 No2000-05-302015-11-20Canada
US5344658 No1994-09-062011-09-06Us
US5854270 Yes1996-05-202016-05-20Us
US5955488 Yes1996-05-142016-05-14Us
US6063802 Yes1996-05-142016-05-14Us
US8580830 No2009-11-232029-11-23Us
US9095577 No2010-07-132030-07-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.248 mg/mLALOGPS
logP2.56ALOGPS
logP2.35ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)15.39ChemAxon
pKa (Strongest Basic)7.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area39.82 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity86.78 m3·mol-1ChemAxon
Polarizability33.16 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, “Process for preparing ondansetron.” U.S. Patent US5478949, issued September, 1990.

US5478949
General References
  1. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. [PubMed:11919526 ]
  2. Yilmaz HL, Yildizdas RD, Sertdemir Y: Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. doi: 10.1111/j.1365-2036.2009.04145.x. Epub . [PubMed:19758398 ]
  3. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240 ]
  4. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177 ]
External Links
ATC CodesA04AA01
AHFS Codes
  • 56:22.20
PDB EntriesNot Available
FDA labelDownload (126 KB)
MSDSDownload (53.2 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Ondansetron can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Ondansetron is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ondansetron.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ondansetron.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ondansetron.
AlmotriptanOndansetron may increase the serotonergic activities of Almotriptan.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ondansetron.
AmantadineAmantadine may increase the QTc-prolonging activities of Ondansetron.
AmiodaroneOndansetron may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Ondansetron can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ondansetron.
AmitriptylineOndansetron may increase the serotonergic activities of Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amperozide.
AmphetamineOndansetron may decrease the stimulatory activities of Amphetamine.
AnagrelideOndansetron may increase the QTc-prolonging activities of Anagrelide.
ApomorphineOndansetron may increase the hypotensive activities of Apomorphine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Ondansetron.
AprepitantThe serum concentration of Ondansetron can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Ondansetron.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ondansetron.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Ondansetron.
Arsenic trioxideOndansetron may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherOndansetron may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Ondansetron can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Articaine.
AsenapineOndansetron may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ondansetron.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Ondansetron.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ondansetron.
AzaperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Azaperone.
AzelastineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ondansetron.
AzithromycinOndansetron may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Ondansetron can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.
BedaquilineOndansetron may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzocaine.
BenzphetamineOndansetron may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzyl alcohol.
BetaxololThe metabolism of Ondansetron can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Ondansetron can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Ondansetron can be decreased when combined with Boceprevir.
BortezomibBortezomib may increase the QTc-prolonging activities of Ondansetron.
BosentanThe serum concentration of Ondansetron can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
BrimonidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ondansetron.
BromocriptineOndansetron may increase the serotonergic activities of Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ondansetron.
BuprenorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Buprenorphine.
BupropionThe metabolism of Ondansetron can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Ondansetron.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ondansetron.
BuspironeOndansetron may increase the serotonergic activities of Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ondansetron.
ButacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ondansetron.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ondansetron.
CabergolineOndansetron may increase the serotonergic activities of Cabergoline.
CaffeineThe metabolism of Ondansetron can be decreased when combined with Caffeine.
CapecitabineThe metabolism of Ondansetron can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ondansetron.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carisoprodol.
CelecoxibThe metabolism of Ondansetron can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ondansetron can be increased when it is combined with Ceritinib.
CeritinibOndansetron may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ondansetron.
ChlormezanoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloroprocaine.
ChloroquineOndansetron may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Ondansetron can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorphenamine.
ChlorphentermineOndansetron may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Ondansetron can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Ondansetron can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ondansetron can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Ondansetron can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ondansetron.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ondansetron.
CisaprideOndansetron may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ondansetron.
CitalopramOndansetron may increase the QTc-prolonging activities of Citalopram.
ClarithromycinOndansetron may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Ondansetron can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clidinium.
ClobazamThe metabolism of Ondansetron can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ondansetron.
ClotrimazoleThe metabolism of Ondansetron can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Ondansetron can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clozapine.
CobicistatThe serum concentration of Ondansetron can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ondansetron.
ConivaptanThe serum concentration of Ondansetron can be increased when it is combined with Conivaptan.
CrizotinibOndansetron may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Ondansetron can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ondansetron.
CyclobenzaprineOndansetron may increase the serotonergic activities of Cyclobenzaprine.
CyclosporineThe metabolism of Ondansetron can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Ondansetron can be decreased when it is combined with Cyproterone acetate.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Ondansetron.
DantroleneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.
DapoxetineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dapoxetine.
DarifenacinThe metabolism of Ondansetron can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Ondansetron can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ondansetron can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ondansetron can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Ondansetron.
DelavirdineThe metabolism of Ondansetron can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Ondansetron is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Ondansetron.
DesfluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ondansetron.
DesipramineOndansetron may increase the serotonergic activities of Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ondansetron.
DesvenlafaxineOndansetron may increase the serotonergic activities of Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Detomidine.
DexamethasoneThe serum concentration of Ondansetron can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ondansetron.
DextroamphetamineOndansetron may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ondansetron.
DextromethorphanOndansetron may increase the serotonergic activities of Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ondansetron.
DezocineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ondansetron.
DifenoxinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ondansetron.
DihydroergotamineOndansetron may increase the serotonergic activities of Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydromorphine.
DiltiazemThe metabolism of Ondansetron can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ondansetron.
DiphenhydramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Diphenoxylate.
DisopyramideOndansetron may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Ondansetron can be decreased when combined with Disulfiram.
DofetilideOndansetron may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Ondansetron.
DomperidoneOndansetron may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ondansetron.
DoxepinOndansetron may increase the serotonergic activities of Doxepin.
DoxycyclineThe metabolism of Ondansetron can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
DoxylamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ondansetron is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
DronedaroneOndansetron may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Ondansetron can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ondansetron.
DrotebanolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ondansetron.
DuloxetineOndansetron may increase the serotonergic activities of Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.
EcgonineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ondansetron is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Ondansetron can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ondansetron is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ondansetron.
EletriptanOndansetron may increase the serotonergic activities of Eletriptan.
EliglustatOndansetron may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Ondansetron can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ondansetron.
EntacaponeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Entacapone.
EnzalutamideThe serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ondansetron.
Ergoloid mesylateOndansetron may increase the serotonergic activities of Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ondansetron.
ErgonovineOndansetron may increase the serotonergic activities of Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ondansetron.
ErgotamineOndansetron may increase the serotonergic activities of Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Ondansetron.
ErythromycinOndansetron may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Ondansetron can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ondansetron.
EscitalopramOndansetron may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ondansetron can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ondansetron.
EthanolOndansetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ondansetron.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.
EthosuximideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.
EtoperidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etorphine.
EtravirineThe serum concentration of Ondansetron can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Ondansetron.
EzogabineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Ondansetron.
FelbamateFelbamate may increase the QTc-prolonging activities of Ondansetron.
FelbamateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ondansetron.
FentanylOndansetron may increase the serotonergic activities of Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.
FexofenadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Ondansetron.
FlecainideOndansetron may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flibanserin.
FloxuridineThe metabolism of Ondansetron can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Ondansetron.
FludiazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunitrazepam.
FluorouracilThe metabolism of Ondansetron can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ondansetron.
FluoxetineOndansetron may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolOndansetron may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ondansetron.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ondansetron.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ondansetron.
FluspirileneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Ondansetron can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Ondansetron.
FosamprenavirThe metabolism of Ondansetron can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ondansetron can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ondansetron.
FosphenytoinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ondansetron.
FrovatriptanOndansetron may increase the serotonergic activities of Frovatriptan.
Fusidic AcidThe serum concentration of Ondansetron can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ondansetron is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ondansetron.
GalantamineGalantamine may increase the QTc-prolonging activities of Ondansetron.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ondansetron is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Ondansetron can be decreased when combined with Gemfibrozil.
GemifloxacinOndansetron may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Glutethimide.
GoserelinGoserelin may increase the QTc-prolonging activities of Ondansetron.
GranisetronGranisetron may increase the QTc-prolonging activities of Ondansetron.
GuanfacineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ondansetron.
HaloperidolThe metabolism of Ondansetron can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Ondansetron.
HydrocodoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.
Hydroxyamphetamine hydrobromideOndansetron may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
HydroxyzineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Ondansetron.
IbutilideOndansetron may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Ondansetron can be increased when it is combined with Idelalisib.
IloperidoneOndansetron may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ondansetron.
ImatinibThe metabolism of Ondansetron can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ondansetron.
ImipramineOndansetron may increase the serotonergic activities of Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ondansetron.
IndalpineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Ondansetron.
IndinavirThe metabolism of Ondansetron can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Ondansetron can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Ondansetron can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ondansetron.
IsocarboxazidOndansetron may increase the serotonergic activities of Isocarboxazid.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ondansetron.
IsofluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Isoflurane.
IsoniazidThe metabolism of Ondansetron can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Ondansetron.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Ondansetron.
IvabradineIvabradine may increase the QTc-prolonging activities of Ondansetron.
IvacaftorThe serum concentration of Ondansetron can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Ondansetron.
LamotrigineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Ondansetron.
LeflunomideThe metabolism of Ondansetron can be decreased when combined with Leflunomide.
LenvatinibOndansetron may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ondansetron.
LevetiracetamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levodopa.
LevofloxacinOndansetron may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ondansetron.
LidocaineThe metabolism of Ondansetron can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ondansetron.
LinezolidOndansetron may increase the serotonergic activities of Linezolid.
LisdexamfetamineOndansetron may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Ondansetron.
LithiumOndansetron may increase the serotonergic activities of Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lofentanil.
LopinavirOndansetron may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Ondansetron can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ondansetron.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ondansetron.
LorcaserinOndansetron may increase the serotonergic activities of Lorcaserin.
LosartanThe metabolism of Ondansetron can be decreased when combined with Losartan.
LovastatinThe metabolism of Ondansetron can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ondansetron.
Lu AA21004The risk or severity of adverse effects can be increased when Ondansetron is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ondansetron can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ondansetron can be decreased when it is combined with Lumacaftor.
LumefantrineOndansetron may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Ondansetron can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ondansetron.
MaprotilineOndansetron may increase the serotonergic activities of Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Ondansetron.
MelatoninThe risk or severity of adverse effects can be increased when Ondansetron is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Melperone.
MephentermineOndansetron may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.
MequitazineOndansetron may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ondansetron.
MethadoneOndansetron may increase the serotonergic activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methadyl Acetate.
MethamphetamineOndansetron may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ondansetron.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ondansetron.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ondansetron.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ondansetron.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ondansetron.
MetoprololThe metabolism of Ondansetron can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ondansetron.
MetyrosineOndansetron may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Ondansetron.
MexiletineThe metabolism of Ondansetron can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.
MifepristoneMifepristone may increase the QTc-prolonging activities of Ondansetron.
MilnacipranThe risk or severity of adverse effects can be increased when Ondansetron is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
MirabegronMirabegron may increase the QTc-prolonging activities of Ondansetron.
MirtazapineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ondansetron.
MitotaneThe serum concentration of Ondansetron can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ondansetron.
MoclobemideOndansetron may increase the serotonergic activities of Moclobemide.
ModafinilThe serum concentration of Ondansetron can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Ondansetron.
MolindoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ondansetron.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ondansetron.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
NabiloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Nabilone.
NafcillinThe serum concentration of Ondansetron can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ondansetron.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ondansetron.
NaratriptanOndansetron may increase the serotonergic activities of Naratriptan.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ondansetron.
NefazodoneOndansetron may increase the serotonergic activities of Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Ondansetron.
NetupitantThe serum concentration of Ondansetron can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ondansetron can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Ondansetron.
NicotineThe metabolism of Ondansetron can be decreased when combined with Nicotine.
NilotinibOndansetron may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Ondansetron can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ondansetron.
NormethadoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ondansetron.
NortriptylineOndansetron may increase the serotonergic activities of Nortriptyline.
OctreotideOctreotide may increase the QTc-prolonging activities of Ondansetron.
OfloxacinOndansetron may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ondansetron.
OlaparibThe metabolism of Ondansetron can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ondansetron.
OlopatadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olopatadine.
OmeprazoleThe metabolism of Ondansetron can be decreased when combined with Omeprazole.
OpiumThe risk or severity of adverse effects can be increased when Ondansetron is combined with Opium.
OrphenadrineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ondansetron.
OsanetantThe risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant.
OsimertinibThe serum concentration of Ondansetron can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ondansetron.
OxprenololThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ondansetron.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ondansetron.
OxymorphoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxymorphone.
OxytocinOxytocin may increase the QTc-prolonging activities of Ondansetron.
PalbociclibThe serum concentration of Ondansetron can be increased when it is combined with Palbociclib.
PaliperidoneOndansetron may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ondansetron.
PanobinostatOndansetron may increase the arrhythmogenic activities of Panobinostat.
PanobinostatThe metabolism of Ondansetron can be decreased when combined with Panobinostat.
ParaldehydeOndansetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ondansetron.
ParoxetineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Ondansetron.
PazopanibOndansetron may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Ondansetron.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ondansetron.
PerampanelThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Ondansetron.
PerospironeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ondansetron.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ondansetron.
PethidineOndansetron may increase the serotonergic activities of Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ondansetron.
PhenelzineOndansetron may increase the serotonergic activities of Phenelzine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenoxyethanol.
PhentermineOndansetron may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenytoin.
PimozideOndansetron may increase the QTc-prolonging activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ondansetron.
PipamperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Ondansetron.
PramipexoleOndansetron may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ondansetron.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ondansetron.
PrimaquineOndansetron may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Primidone.
ProcainamideOndansetron may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ondansetron.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ondansetron.
ProcarbazineOndansetron may increase the serotonergic activities of Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.
PromazineThe metabolism of Ondansetron can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ondansetron.
PromethazineOndansetron may increase the serotonergic activities of Promethazine.
PropafenoneOndansetron may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ondansetron.
PropofolPropofol may increase the QTc-prolonging activities of Ondansetron.
PropofolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ondansetron.
ProtriptylineOndansetron may increase the serotonergic activities of Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ondansetron is combined with PSD502.
PyrimethamineThe metabolism of Ondansetron can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Quazepam.
QuetiapineOndansetron may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ondansetron.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ondansetron.
QuinidineOndansetron may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Ondansetron can be decreased when combined with Quinidine.
QuinineOndansetron may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Ondansetron can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ramelteon.
RanolazineRanolazine may increase the QTc-prolonging activities of Ondansetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ondansetron.
RasagilineOndansetron may increase the serotonergic activities of Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ondansetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ondansetron.
RifabutinThe metabolism of Ondansetron can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ondansetron can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ondansetron can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ondansetron.
RisperidoneRisperidone may increase the QTc-prolonging activities of Ondansetron.
RisperidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Risperidone.
RitonavirRitonavir may increase the QTc-prolonging activities of Ondansetron.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ondansetron.
RizatriptanOndansetron may increase the serotonergic activities of Rizatriptan.
RolapitantThe metabolism of Ondansetron can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Romifidine.
RopiniroleOndansetron may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Ondansetron can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron.
RotigotineOndansetron may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ondansetron.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ondansetron is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ondansetron.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ondansetron.
SaquinavirOndansetron may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ondansetron.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ondansetron.
SelegilineOndansetron may increase the serotonergic activities of Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ondansetron.
SevofluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sevoflurane.
SildenafilThe metabolism of Ondansetron can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ondansetron can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ondansetron can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ondansetron.
SorafenibSorafenib may increase the QTc-prolonging activities of Ondansetron.
SotalolOndansetron may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Ondansetron can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.
SulfadiazineThe metabolism of Ondansetron can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ondansetron.
SulfisoxazoleOndansetron may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Ondansetron can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ondansetron.
SumatriptanOndansetron may increase the serotonergic activities of Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Ondansetron.
SuvorexantThe risk or severity of adverse effects can be increased when Ondansetron is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ondansetron.
TapentadolOndansetron may decrease the analgesic activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ondansetron.
TasimelteonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ondansetron.
Tedizolid PhosphateOndansetron may increase the serotonergic activities of Tedizolid Phosphate.
TelaprevirThe metabolism of Ondansetron can be decreased when combined with Telaprevir.
TelavancinOndansetron may increase the QTc-prolonging activities of Telavancin.
TelithromycinOndansetron may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ondansetron.
TenofovirThe metabolism of Ondansetron can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Ondansetron can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ondansetron.
TeriflunomideThe serum concentration of Ondansetron can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ondansetron.
TetrabenazineOndansetron may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrodotoxin.
ThalidomideOndansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ondansetron.
TheophyllineThe metabolism of Ondansetron can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ondansetron.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ondansetron.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ondansetron.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ondansetron.
ThiothixeneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiagabine.
TicagrelorThe metabolism of Ondansetron can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Ondansetron can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiletamine.
TipranavirThe metabolism of Ondansetron can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Ondansetron.
TizanidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tizanidine.
TocilizumabThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Ondansetron can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Ondansetron.
TopiramateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Topiramate.
ToremifeneOndansetron may increase the QTc-prolonging activities of Toremifene.
TramadolOndansetron may decrease the analgesic activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ondansetron.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ondansetron.
TranylcypromineOndansetron may increase the serotonergic activities of Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ondansetron.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ondansetron.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ondansetron.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ondansetron.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ondansetron.
TrimipramineOndansetron may increase the serotonergic activities of Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ondansetron.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ondansetron.
ValsartanThe metabolism of Ondansetron can be decreased when combined with Valsartan.
VandetanibOndansetron may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Ondansetron.
VemurafenibThe serum concentration of Ondansetron can be increased when it is combined with Vemurafenib.
VemurafenibOndansetron may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ondansetron.
VenlafaxineOndansetron may increase the serotonergic activities of Venlafaxine.
VerapamilThe metabolism of Ondansetron can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Ondansetron.
VilazodoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vilazodone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Ondansetron.
VorinostatVorinostat may increase the QTc-prolonging activities of Ondansetron.
VortioxetineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Xylazine.
YohimbineThe therapeutic efficacy of Ondansetron can be decreased when used in combination with Yohimbine.
ZafirlukastThe metabolism of Ondansetron can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zimelidine.
ZiprasidoneOndansetron may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Ondansetron can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ondansetron.
ZolmitriptanOndansetron may increase the serotonergic activities of Zolmitriptan.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ondansetron.
ZonisamideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zotepine.
ZuclopenthixolOndansetron may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ondansetron.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Artaiz I, Zazpe A, Del Rio J: Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. Behav Pharmacol. 1998 Mar;9(2):103-12. [PubMed:10065930 ]
  2. Fortuno A, Ballaz S, Del Rio J, Barber A: CCK-mediated response in the activation of 5-HT receptor types in the guinea-pig ileum. J Physiol Biochem. 1999 Jun;55(2):85-92. [PubMed:10517265 ]
  3. Llacer JM, Gallardo V, Delgado R, Parraga J, Martin D, Ruiz MA: X-ray diffraction and electron microscopy in the polymorphism study of ondansetron hydrochloride. Drug Dev Ind Pharm. 2001 Oct;27(9):899-908. [PubMed:11763467 ]
  4. Carvalho F, Macedo D, Bandeira I, Maldonado I, Salles L, Azevedo MF, Rocha MA Jr, Fregoneze JB, De Castro-e-Silva E: Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm Metab Res. 2002 Feb;34(2):55-61. [PubMed:11972287 ]
  5. Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A: Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg. 2002 Jun;94(6):1553-7, table of contents. [PubMed:12032025 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Gallardo Lara V, Gallardo ML, Morales Hernandez ME, Ruiz Martinez MA: Ondansetron: design and development of oral pharmaceutical suspensions. Pharmazie. 2009 Feb;64(2):90-3. [PubMed:19320280 ]
  8. Mohan KC, Ravikumar K: Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker. Acta Crystallogr C. 1995 Dec 15;51 ( Pt 12):2627-9. [PubMed:8588861 ]
  9. Dimitrov DH: Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C. Prim Care Companion J Clin Psychiatry. 2009;11(6):366-7. doi: 10.4088/PCC.08l00755. [PubMed:20098535 ]
  10. Szajewska H, Gieruszczak-Bialek D, Dylag M: Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007 Feb 15;25(4):393-400. [PubMed:17269994 ]
  11. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. [PubMed:11919526 ]
  12. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240 ]
  13. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR4
Uniprot ID:
Q13639
Molecular Weight:
43760.975 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26. [PubMed:16192915 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 03:39